Ovulation Double Check (Proov) Verification and Usability Testing

• ClinicalTrials.gov Identifier: NCT03924440
• Recruitment Status: Enrolling by invitation
• First Posted: April 23, 2019
• Last Update Posted: September 3, 2020
• Sponsor: MFB Fertility
• Information provided by (Responsible Party): MFB Fertility

Study Description

Brief Summary:

The Ovulation Double Check test is a Class I, 510K exempt medical device. It is manufactured and packaged in an FDA-registered and cGMP compliant facility. This device measures the level of Pregnanediol (PdG), the major urine metabolite of progesterone, in the urine of women. PdG has been shown to increase significantly after ovulation has occurred. This test will be used in a home setting as a point-of-care device, providing couples additional information about menstrual cycling and possible fertile periods. The investigators have successfully developed prototype devices that can accurately measure PdG in urine. Now the investigators need to supply these prototype devices to end users to verify the assay is working correctly and determine if the device was designed properly in order for home users to 1) use the test properly, 2) read the test results properly, and 3) interpret the results correctly.

Condition or disease	Intervention/treatment
Ovulation Disorder	Diagnostic Test: Proov (Ovulation Double Check) Test

Detailed Description:

Lack of or insufficient ovulatory events is the primary cause of infertility worldwide and with 12% of couples within the US being diagnosed with infertility each year (according to the CDC), thus being able to confirm ovulation is an essential component of infertility evaluations in women. The gold standards for confirming ovulation include transvaginal ultrasounds and serum progesterone blood draws. Both of these techniques are too invasive, too expensive, and/or inaccessible to most women. Therefore a non-invasive, inexpensive, home-based testing system to confirm ovulation is desired. Several recent studies have identified urinary pregnanediol levels as an accurate way to confirm ovulation. However, until now, urine pregnanediol levels were always measured via a lab setting. Here the investigators describe the development of a urine pregnanediol (PDG) rapid test and its use at confirming ovulation in a home environment. Study Protocol One hundred and ninety six women were recruited to take part in a prospective, blinded cohort home environment study. The study protocol was approved by the Ethics Committee at Solutions IRB. Detailed information about the study was provided to each volunteer, and informed consent was obtained prior the study commencement. Inclusion criteria were non-pregnant women residing within the United States, aged 18- 45, and not currently on hormonal birth control. Importantly, women were not excluding due to average cycle length, weight (BMI), breastfeeding status, poly-cyctic ovarian syndrome (PCOS) or any other cause of infertility or lifestyle factor. Participants were asked to predict ovulation by monitoring changes in cervical mucus and/or tracking luteinizing hormone (LH) via home test kits. Participants were asked to self-report their peak fertility day, which was defined as the first LH surge day and/or day of peak cervical mucus (stretchy and eggwhite in consistence).

Participants collected first morning urine as various times during their cycle, including, prior to, during, and after peak fertility signs were observed. Participants were provided PDG rapid response test strips and self-administered the tests and recorded the results. Test results were reported back the investigators via a log sheet. Log sheets recorded testing date, day of cycle, date of peak fertility (if known), personal assessment of results (positive result vs negative result) and a place to tape the completed test strip.

Study Design

• Study Type: Observational
• Actual Enrollment: 196 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Characterization and Use of Urine Pregnanediol Rapid Test and Its Use for Confirming Ovulation - Proov (Ovulation Double Check) Test
• Actual Study Start Date: October 1, 2016
• Estimated Primary Completion Date: December 31, 2021
• Estimated Study Completion Date: December 31, 2021

Groups and Cohorts

Group/Cohort

Intervention/treatment

PDG Test strip Users; Participants were asked to predict ovulation by monitoring changes in cervical mucus and/or tracking luteinizing hormone (LH) via home test kits. Participants were asked to self-report their peak fertility day, which was defined as the first LH surge day and/or day of peak cervical mucus (stretchy and eggwhite in consistence). Participants collected first morning urine as various times during their cycle, including, prior to, during, and after peak fertility signs were observed. Participants were provided PDG rapid response test strips and self-administered their tests and recorded their results. Test results were reported back researchers via a log sheet. Log sheets recorded testing date, day of cycle, date of peak fertility (if known), personal assessment of results (positive result vs negative result) and a place to tape the completed test strip.

Diagnostic Test: Proov (Ovulation Double Check) Test; Rapid response urine progesterone test strips, Proov (formerly named Ovulation Double Check

Outcome Measures

Primary Outcome Measures :

1. Number if participants with positive PDG test results [ Time Frame: A single menstrual cycle, up to 45 days. ]
   PDG test results are recorded to determine when PDG test results were positive

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 34 Years (Adult)
• Sexes Eligible for Study: Female
• Gender Based Eligibility: Yes
• Gender Eligibility Description: Women only due to ovulation tracking diagnostic studied
• Sampling Method: Non-Probability Sample

Study Population

Inclusion criteria were non-pregnant women residing within the United States, aged 18-34, and not currently on hormonal birth control. Importantly, women were not excluding due to average cycle length, weight (BMI), breastfeeding status, poly-cyctic ovarian syndrome (PCOS) or any other cause of infertility or lifestyle factor.

Criteria

Inclusion Criteria:

1. Female (mandatory)
2. Not currently pregnant or nursing (pregnancy affects PdG levels)
3. Aged 18-34 (advanced age can hinder PdG levels)
4. Cycle length of 26-39 days (long or short cycles have inconsistent PdG levels)
5. Currently use other fertility monitoring tools (this allows us to compare Proov - Ovulation Double Check test results with other fertility tracking methods)

Exclusion Criteria:

1. Male
2. Pregnant
3. Nursing

Contacts and Locations

Sponsors and Collaborators

MFB Fertility

Investigators

• Principal Investigator: Amy Beckley, PhD; MFB Fertility

More Information

• Responsible Party: MFB Fertility
• ClinicalTrials.gov Identifier: NCT03924440
• Other Study ID Numbers: 09/19/2016
• First Posted: April 23, 2019
• Last Update Posted: September 3, 2020
• Last Verified: September 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Nonoxynol; Spermatocidal Agents; Antispermatogenic Agents; Physiological Effects of Drugs; Contraceptive Agents, Female; Contraceptive Agents; Reproductive Control Agents; Contraceptive Agents, Male